Business Wire

ONWARD’s Research Partner .NeuroRestore Publishes Groundbreaking Paper Identifying Neurons that Restore Walking after Paralysis

Share

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported that a new study by scientists at .NeuroRestore, ONWARD’s research partner, has identified the specific neurons that are activated and remodeled by spinal cord stimulation, enabling individuals with spinal cord injury to stand, walk and rebuild their muscles. This discovery marks a fundamental, scientific breakthrough. The study was published yesterday in Nature.

In the multi-year STIMO study, coordinated by .NeuroRestore’s co-directors – Grégoire Courtine, a neuroscience professor at EPFL and Chief Scientific Officer of ONWARD, and Jocelyne Bloch, a neurosurgeon at Lausanne University Hospital (CHUV) – participants with paralysis due to spinal cord injury underwent targeted epidural electrical stimulation of the area of the spinal cord that controls leg movement. Remarkably, all participants regained motor function and the ability to walk. Three participants in the study pioneered use of an innovative lead developed by ONWARD to specifically target the areas of the spinal cord involved in leg and lower trunk movement with the intent to facilitate faster and more effective recovery of motor function.

The scientists believe it is crucial to understand exactly how neuronal reorganization occurs to develop more effective treatments and improve the lives of as many people as possible. The press release by EPFL can be found here.

“The findings published yesterday continue to build our strong knowledge base in spinal cord stimulation to help people with paralysis. As a result of this study and its accompanying scientific breakthrough, ONWARD and its research partners have learned precisely where to place the epidural lead and how to program stimulation to facilitate walking,” said Dave Marver, CEO of ONWARD. “This important work is enabling us to develop a therapy for people with spinal cord injury that aims to be precise, repeatable, and scalable.”

About ONWARD Medical

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries. ONWARD’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD’s ARC Therapy, which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.

ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IMand ARC-EX. ARC-EX is an external, non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company’s first pivotal study, called Up-LIFT, evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.

ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The company has an academic partnership with .NeuroRestore, a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

Disclaimer

Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Company Enquiries:
info@onwd.com

For Media Enquiries:
MC Services AG
U.S.: Laurie Doyle, P: +1 339 832 0752
Europe: Dr. Johanna Kobler, Katja Arnold, Kaja Skorka P: +49 89 210 228 0
media@onwd.com

For Investor Enquiries:
investors@onwd.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nordic Companies Warm to Automation as Platforms Evolve8.12.2022 10:00:00 CET | Press release

Enterprise use of AI-powered automation platforms has soared over the past year in the Nordics, although challenges to enterprise and public sector adoption remain, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2022 ISG Provider Lens™ Intelligent Automation — Platforms and Products report for the Nordics finds that the recent surge in adoption has been triggered by several converging factors. The high cost of labor in the Nordics has generated demand for automation to replace some tasks, while enterprises are also embracing the new technologies to ensure employee well-being and productivity as they ask team members to return to the office. These trends are accelerating against the backdrop of a general move toward enterprise digital transformation across the Nordics and other developed regions. “Intelligent automation is meeting emerging needs at companies in the Nordics,

REPLY: Arlanis Reply Named Salesforce Implementation Partner of the Year and Community Impact Partner of the Year8.12.2022 09:30:00 CET | Press release

Arlanis Reply, the Reply Group company specialized in Salesforce solutions and services, has been recognized with two awards from Salesforce for its outstanding performance as a partner in the categories "Salesforce Implementation Partner of the Year" and "Community Impact Partner of the Year" in Germany, Austria and Switzerland. With these Partner Awards, Salesforce annually honours partner companies that have demonstrated exceptional commitment to consistently delivering high-quality implementations and business outcomes for their clients. The award for the "Salesforce Implementation Partner" was given in recognition of the variety, complexity and number of customer projects with the highest customer satisfaction. As a long-standing Salesforce Consulting Partner, Arlanis Reply convinced the jury with profound expertise and comprehensive knowledge of the entire Salesforce portfolio – as well as high quality in numerous, cross-industry customer projects. The second "Community Impact Pa

ADVA’s new OSA 3350 SePRC ™ optical cesium clock breaks records with industry’s longest holdover8.12.2022 09:00:00 CET | Press release

ADVA (FSE: ADV) today launched its latest optical cesium atomic clock solution, providing unprecedented protection for critical network infrastructure systems that rely on synchronization from GNSS. The new OSA 3350 Super ePRC (SePRC™) delivers extensive timing holdover with high-performance stability and lifetime that significantly outperforms any other solution on the market. It offers a vital lifeline to time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS) providers, defense organizations, communication network operators, power utilities and transportation network operators looking to mitigate the risk of jamming and spoofing attacks. As a GBaaS solution, the OSA 3350 SePRC™ provides a backup to satellite-based synchronization, helping prevent severe harm to businesses and society that long GNSS outages can cause. The new device will enable the most robust PNT solution on the market. “Across all nations, our well-being and safety are more dependent than ever on critical net

Record-Breaking Demand for Alternative Residence and Citizenship8.12.2022 08:39:00 CET | Press release

The number of high-net-worth individuals enquiring about investment migration options has more than doubled since the coronavirus was first reported three years ago, with record numbers of wealthy international investors now looking to diversify their residence and citizenship options amid unprecedented global volatility. Henley & Partners has also seen a huge surge in interest and applications from citizens of highly developed countries such as Canada, the UK, and the US compared to pre-pandemic times, with Americans now the top client nationality seeking alternative residence and/or additional citizenship. Henley & Partners CEO Dr. Juerg Steffen says with many economies now in a post-pandemic phase plagued by security, political, and economic risks, wealthy families are revisiting their priorities to ensure that their legacies, wealth, and lifestyles are protected and future-proofed. “For high-net-worth investors, the optionality of living in or conducting business in a country of th

Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events8.12.2022 08:00:00 CET | Press release

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3 Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C